Abstract
Cancer tissues are often found to contain immune cells in their vicinity, which naturally leads to the question of a relationship between immune cells and tumors and whether the former actually help or suppress cancer progression. Numerous studies have now shown evidence for both scenarios. Lately, however, the ability of our immune response to induce apoptosis, or programmed cell death, in cancer cells and so to fight against disease progression is gaining momentum. Among the many immune factors found within the tumor microenvironment, the tumor necrosis factor (TNF) family members are noted for their ability to induce cellular apoptosis, in addition to typical proinflammatory response. In particular, the TNF-related apoptosis ligand (TRAIL), also known as Apo-2 ligand and TNFSF10, has received primal attention as these are capable of recognizing and inducing apoptosis of tumors and metastases while leaving normal cells mostly unaffected.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Finn OJ (2008) Cancer immunology. N Engl J Med 358:2704–2715
Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8:59–73
Yang A, Wilson NS, Ashkenazi A (2010) Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. Curr Opin Cell Biol 22:837–844
Frew AJ, Lindemann RK, Martin BP, Clarke CJ, Sharkey J, Anthony DA, Banks KM, Haynes NM, Gangatirkar P, Stanley K, Bolden JE, Takeda K, Yagita H, Secrist JP, Smyth MJ, Johnstone RW (2008) Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci USA 105:11317–11322
Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL (2012) On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene. doi:10.1038/onc.2012.164
Jin CY, Park C, Kim GY, Lee SJ, Kim WJ, Choi YH (2009) Genistein enhances TRAIL-induced apoptosis through inhibition of p38 MAPK signaling in human hepatocellular carcinoma Hep3B cells. Chem Biol Interact 180:143–150
Ammann JU, Haag C, Kasperczyk H, Debatin K, Fulda S (2009) Sensitization of neuroblastoma cells for TRAIL-induced apoptosis by NF-κB inhibition. Int J Cancer 124:1301–1311
Baxevanis CN, Perez SA, Papamichail M (2009) Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother 58:317–324
Tsuchiya M, Piras V, Choi S, Akira S, Tomita M, Giuliani A, Selvarajoo K (2009) Emergent genome-wide control in wildtype and genetically mutated lipopolysaccarides-stimulated macrophages. PLoS One 4:e4905
Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D, Ashkenazi A (2005) Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 280:40599–40608
Piras V, Hayashi K, Tomita M, Selvarajoo K (2011) Enhancing apoptosis in TRAIL-resistant cancer cells using fundamental response rules. Sci Rep 1:144
Xu J, Zhou J, Wei W, Wu GS (2010) Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. PLoS One 5:e10226
Li P, Jayarama S, Ganesh L, Mordi D, Carr R, Kanteti P, Hay N, Prabhakar BS (2010) Akt-phosphorylated mitogen-activated kinase-activating death domain protein (MADD) inhibits TRAIL-induced apoptosis by blocking Fas-associated death domain (FADD) association with death receptor 4. J Biol Chem 285:22713–22722
He M, Wang Y, Li W (2009) PPI finder: a mining tool for human protein–protein interactions. PLoS One 4:e4554
Hirai T, Chida K (2003) Protein kinase Cζ (PKCζ): activation mechanisms and cellular functions. J Biochem 133:1–7
Selvarajoo K (2011) Macroscopic law of conservation revealed in the population dynamics of Toll-like receptor signaling. Cell Commun Signal 9:9
Selvarajoo K (2012) Understanding multimodal biological decisions from single cell and population dynamics. Wiley Interdiscipl Rev Syst Biol Med 4:385–399
Piras V, Tomita M, Selvarajoo K (2012) Is central dogma a global property of cellular information flow? Front Physiol 3:439
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Selvarajoo, K. (2013). TRAIL Signaling in Cancer. In: Immuno Systems Biology. Systems Biology, vol 3. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7690-0_8
Download citation
DOI: https://doi.org/10.1007/978-1-4614-7690-0_8
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-7459-3
Online ISBN: 978-1-4614-7690-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)